Hostname: page-component-78c5997874-4rdpn Total loading time: 0 Render date: 2024-11-10T09:10:29.979Z Has data issue: false hasContentIssue false

Advances in treatment in bipolar pregnant patients

Published online by Cambridge University Press:  16 April 2020

A.L. Sutter-Dallay*
Affiliation:
Réseau de Psychiatrie Périnatale, Centre Hospitalier Charles Perrens, Bordeaux, France

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

The perinatal period is a time of psychic vulnerability, in particular with regard to bipolar mood disorders. Chemotherapeutic treatments cannot always be avoided, and raise the question of the influence of the impact of psychotropic drugs on child during pregnancy. The impact study of the drugs on the embryo, the foetus and the new-born baby raises obvious ethical problems, and there is very few work which is often of a debatable methodological quality, because mainly retrospective. The use of mood stabilisers treatments remains discussed, especially with regard to the anticonvulsivants. If the use of neuroleptics are now quite well defined during pregnancy, antipsychotics remain, for the most, molecules in course of evaluation.

Practical and ethical issues of those chemotherapeutic treatment strategies will be discussed, as well as other approaches, as specific pregnancy psychoeducation.

Type
S26. Symposium: Advances in Treatment of Perinatal Mental Disorders
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.